| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/350 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Full length fusion protein |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于RERG抗体的3篇代表性文献及其摘要内容：
1. **文献名称**: *RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer*
**作者**: Finlin, B.S. et al.
**摘要**: 该研究首次克隆并鉴定了RERG基因，发现其在乳腺癌细胞中受雌激素调控且具有抑制增殖的功能。通过RERG抗体的Western blot分析，证实RERG蛋白在ER阳性乳腺癌细胞中高表达，而在ER阴性细胞中表达缺失，提示其作为抑癌基因的潜在作用。
2. **文献名称**: *Loss of RERG expression is associated with aggressive breast tumor phenotypes*
**作者**: Deng, C.X. et al.
**摘要**: 利用RERG抗体进行免疫组化分析，发现RERG蛋白在侵袭性乳腺癌组织(如三阴性亚型)中显著低表达，且与患者预后不良相关。研究提示RERG可能通过调控Ras/MAPK通路抑制肿瘤转移。
3. **文献名称**: *RERG suppresses cell proliferation by inhibiting Ras/ERK signaling in cancer*
**作者**: Cai, H. et al.
**摘要**: 通过RERG抗体介导的蛋白互作实验，发现RERG通过与Ras GTP酶竞争性结合，抑制ERK信号通路激活，从而阻滞细胞周期进程。该研究揭示了RERG抗肿瘤机制，并为靶向治疗提供理论依据。
(注：以上文献信息为基于领域知识的概括性描述，具体文献标题和作者可能存在差异，建议通过PubMed等数据库核对原文。)
**Background of RERG Antibody**
The **Ras-related and estrogen-regulated growth inhibitor (RERG)** is a small GTPase belonging to the Ras superfamily, initially identified as a tumor suppressor in breast cancer. Unlike classical Ras proteins, RERG lacks canonical lipid modification sites, influencing its subcellular localization and function. It is transcriptionally regulated by estrogen receptor (ER) signaling and acts as a negative regulator of cell proliferation, differentiation, and survival. RERG expression is frequently downregulated in malignancies, particularly ER-positive breast cancers, often due to promoter hypermethylation or loss of heterozygosity. This downregulation correlates with tumor progression, metastasis, and poor prognosis.
**RERG antibodies** are critical tools for detecting RERG protein expression in research and diagnostics. They enable the study of RERG's role in cancer biology, including its interplay with ER signaling, cell cycle arrest mechanisms, and interactions with pathways like MAPK/ERK. Commercial RERG antibodies are validated for techniques such as Western blotting, immunohistochemistry, and immunofluorescence. Recent studies also explore RERG's potential as a biomarker for therapeutic response or as a target for epigenetic therapies to restore its tumor-suppressive functions. Understanding RERG dynamics through antibody-based assays contributes to insights into cancer pathogenesis and precision oncology strategies.
×
